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Abstract
A key goal of whole genome sequencing (WGS) for human genetics studies is to interrogate all 
forms of variation, including single nucleotide variants (SNV), small insertion/deletion (indel) 
variants and structural variants (SV). However, tools and resources for the study of SV have 
lagged behind those for smaller variants. Here, we used a scalable pipeline22 to map and 
characterize SV in 17,795 deeply sequenced human genomes. We publicly release site-frequency 
data to create the largest WGS-based SV resource to date. On average, individuals carry 2.9 rare 
SVs that alter coding regions, affecting the dosage or structure of 4.2 genes and accounting for 
4.0-11.2% of rare high-impact coding alleles. Based on a computational model, we estimate that 
SVs account for 17.2% of rare alleles genome-wide with predicted deleterious effects equivalent to 
loss-of-function coding alleles; ~90% of such SVs are non-coding deletions (mean 19.1 per 
genome). We report 158,991 ultra-rare SVs and show that ~2% of individuals carry ultra-rare 
megabase-scale SVs, nearly half of which are balanced or complex rearrangements. Finally, we 
infer the dosage sensitivity of genes and non-coding elements, revealing trends related to element 
class and conservation. This work will help guide SV analysis and interpretation in the era of 
WGS.
INTRODUCTION
Human genetics studies employ WGS to enable comprehensive trait mapping analyses 
across the full diversity of genome variation, including SVs (≥50 bp) such as deletions, 
duplications, insertions, inversions and other rearrangements. Prior work suggests a 
disproportionately large role for SVs (relative to their abundance) in rare disease biology1, 
and in shaping heritable gene expression differences in the human population2–4. Rare and 
de novo SV have been implicated in the genetics of autism5–9 and schizophrenia10–13, but 
few other complex trait association studies have directly assessed SV14,15.
One challenge for SV interpretation in WGS-based studies is the lack of high-quality 
publicly available variant maps from large populations. Our current knowledge is based 
primarily on three sources: (1) a large and disparate collection of array-based studies16–18, 
with limited allele frequency data and low resolution; (2) the 1000 Genomes Project callset4, 
which has been invaluable but is limited by the modest sample size and low coverage design; 
and (3) an assortment of smaller WGS-based studies with varied coverage, technologies, 
analysis methods, and levels of data accessibility7,8,19–21.
There is an opportunity to improve knowledge of SV in human populations via systematic 
analysis of large-scale WGS data resources generated by programs such as the NHGRI 
Centers for Common Disease Genomics (CCDG). A key barrier to the creation of larger and 
more informative SV catalogs is the lack of computational tools that can scale to the size of 
ever-growing datasets. To this aim, we have developed a highly scalable open source SV 
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analysis pipeline22, and used it to map and characterize SV in 17,795 deeply sequenced 
human genomes.
RESULTS
A population-scale SV map
The samples analyzed here are derived from common disease case/control and quantitative 
trait mapping collections sequenced under the CCDG program, supplemented with 
ancestrally diverse samples from the PAGE consortium and Simons Genome Diversity 
Panel. The final ancestry composition includes 24% African, 16% Latino, 11% Finnish, 39% 
non-Finnish European, and 9% other diverse samples from around the world (Extended Data 
Table 1).
The tools and pipelines used for this work are described elsewhere22. Briefly, we developed 
a highly scalable software toolkit (svtools) and workflow for large-scale SV callset 
generation that combines per-sample variant discovery23, resolution-aware cross-sample 
merging, breakpoint genotyping24, copy number annotation, and variant classification 
(Extended Data Fig. 1). We created two distinct SV callsets using different reference 
genome and pipeline versions. The “B37” callset includes 118,973 high-confidence SV from 
8,426 samples sequenced at the McDonnell Genome Institute and aligned to the GRCh37 
reference genome. The “B38” callset includes 241,031 high-confidence SV from 23,175 
samples sequenced at four CCDG sites and aligned to GRCh38 using the “functional 
equivalence” pipeline25 (see Methods). Of the 26,347 distinct samples in the union of the 
two callsets, aggregate-level sharing is permitted for 17,795; these comprise the official 
public release (Supplementary Files 1 and 2). For simplicity of presentation, most analyses 
below focus on the larger B38 callset (Supplementary Table 1).
We observed a mean of 4,442 high-confidence SV per genome, predominantly deletions 
(35%), mobile element insertions (27%), and tandem duplications (11%) (Fig. 1b, Extended 
Data Figs. 2 and 3). Variant counts and linkage disequilibrium patterns are consistent with 
prior studies using similar methods4,26, and most SVs are mapped to base-pair resolution 
(Extended Data Figs. 2 and 3). As expected, the site-frequency spectrum approximates that 
of SNV and indels, the size distribution shows increasing length with decreasing frequency, 
and principal components analysis reveals population structure consistent with self-reported 
ancestry (Fig. 1, Extended Data Figs. 2–4). Per-genome SV counts are broadly consistent 
and vary as expected based on ancestry, with more genetic variation in African-ancestry 
individuals and fewer singletons in Finns (Extended Data Figs. 2 and 3). Although we 
observe some technical variability due to cohort and sequencing center, these effects are 
mainly limited to small (<1 kb) CNVs detected solely by read-pair signals, which are 
sensitive to library preparation and alignment filtering methods (see Methods, Extended 
Data Fig. 3).
We further characterized callset quality using independent data and analyses (see 
Supplementary Note) including (i) validation by deep coverage (>52-85x) long-read data 
from nine genomes, (ii) sensitivity relative to a comprehensive long-read callset27, (iii) 
inheritance patterns within a set of 3-generation pedigrees, and (iv) comparison to well-
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characterized short-read callsets4,27 (Supplementary Tables 2–4 and Extended Data Figs. 5–
7). We achieve a validation rate of 84% by long-read data, with higher validation rates for 
the variant classes most relevant to the findings below: deletions (87%), rare SV (90%) and 
singleton SV (95%). Based on the validation rates of SV frequency classes and their relative 
abundance in the full dataset, we estimate a false discovery rate of 7.0%. Although overall 
sensitivity is low (49%) compared to long-read SV maps due to the inherent difficulty of 
detecting repetitive variants from short reads, it is comparable to published short-read 
callsets4,26,27, and substantially higher for functionally relevant subtypes such as SV larger 
than 1 kb (63%) and predicted high impact variants (82%).
Burden of deleterious rare SV
The contribution of rare SV to human disease remains unclear. Well-powered WGS-based 
trait mapping studies will ultimately be required to address this; however, the overall burden 
of predicted pathogenic mutations in the human population is informative and can be 
estimated from our data. Our analysis of 14,623 individuals identified 42,765 rare SV alleles 
(MAF<1%) predicted to decrease gene dosage (n=9,416), alter gene function (e.g., single 
exon deletion; n=26,337), or increase gene dosage (n=7,012). The majority of rare gene-
altering SVs are deletions (54.5%), with fewer duplications (42.2%), and a small fraction of 
other variant types, primarily inversions and complex rearrangements that interrupt or 
rearrange exons. Of these, 23.4% affect multiple genes and 10.4% affect 3 or more genes, 
resulting in a mean of 4.2 SV-altered genes per individual. Based on a strict definition of 
loss-of-function (LoF) SV – gene disruptions and gene deletions affecting >20% of exons – 
we identified a mean of 1.39 rare SV-based gene LoF alleles per person. Analysis of 4,298 
samples with SV and SNV/indel calls reveals that individuals carry a mean of 33.6 rare 
high-confidence LoF SNV and small indels (Fig. 2), consistent with prior studies28. Thus, 
SV accounts for 4-11.2% of rare, predicted high impact gene alterations in a population 
sample, depending on whether we consider all coding SV, or a strictly defined set of LoF 
variants (Fig. 2c). These are likely to be underestimates considering that the false negative 
rate of SV detection is typically higher than that of SNV and small indels24,27.
To characterize the relative impact of different coding SV classes we calculated two 
measures of purifying selection (Fig. 2d): (1) the fraction of variants that affect dosage 
tolerant genes with an LoF intolerance (pLI)28,29 score <0.9 (2) the fraction of variants 
present as “singletons” found in only one individual or family. By these measures, deletions 
are more deleterious than duplications, and complete gene deletions are the most deleterious 
class. Notably, based on the fraction of variants in dosage intolerant genes, complete gene 
duplications and sub-genic deletions affecting <20% of exons are relatively depleted, 
suggesting that many gene-altering SV are strongly deleterious, even if not predicted to 
completely obliterate gene function.
The above calculations ignore missense and non-coding variants that are expected to 
comprise a large fraction of rare functional variation. Predicting the impact of these variant 
types is challenging, but we can approximate their relative contribution to the deleterious 
variant burden under two simplifying assumptions: (1) impact prediction algorithms such as 
CADD30 and LINSIGHT31 are capable of ranking variants within a given class (SNV, indel, 
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SV) by their degree of deleteriousness, and (2) the mean deleterious impact of a given set of 
variants is reflected by its singleton rate. The first assumption is somewhat tenuous, but 
should be valid here given that impact prediction inaccuracies are likely to affect all variant 
classes similarly; the second should hold under an infinite sites model of mutation, which is 
reasonable for the (N=4,298) samples used in this analysis. We note that other evolutionary 
forces such as positive selection, background selection, and biased gene conversion can also 
shape the site frequency spectrum; however, we expect that these forces would act similarly 
on the variant classes examined here, in a genome-wide analysis of a very large number of 
sites.
We used CADD and LINSIGHT to generate impact scores for SNV, indels, deletions and 
duplications (see Methods). As expected, these are highly correlated with singleton rate and 
variant effect predictions from VEP32 and LOFTEE28 (Fig. 3). We sought to identify 
“strongly deleterious” variants from each class by choosing impact score thresholds to match 
the singleton rate of the entire set of high-confidence LoF mutations. Individuals carried a 
mean of 121.9 such “strongly deleterious” rare variants, comprising 63% SNV, 19.8% indels 
and 17.2% SV (Fig. 3d). Given the relative numerical abundance of different rare variant 
classes, this suggests that a given rare SV is 841-fold more likely to be strongly deleterious 
than a rare SNV, and 341-fold more likely than a rare indel. Predicted deleterious SV are 
slightly larger than rare SV on the whole (median 4.5 vs. 2.8 kb). Whereas only a minority 
(13.1%) of predicted strongly deleterious SNV and indels are non-coding, 90.1% of 
predicted strongly deleterious rare SV are non-coding. In particular, the top 50% of non-
coding deletions show similar levels of purifying selection (as measured by singleton rate) as 
high-confidence LoFs caused by SNV/indels (see Fig. 3c), implying that a typical individual 
carries 19.1 strongly deleterious rare non-coding deletion alleles. This suggests that non-
coding deletions may have strong deleterious effects and play a larger than expected role in 
human disease.
Landscape of ultra-rare SV
Most ultra-rare SV represent recent or de novo structural mutations, and thus the relative 
abundance of different ultra-rare SV classes sheds light on the underlying mutational 
processes at work. We identified 158,991 ultra-rare SV (105,175 high-confidence) present in 
only one of 14,623 individuals or private to a family. This corresponds to a mean of ~11.4 
per individual (Extended Data Fig. 8a). Ultra-rare SV are mainly composed of deletions (5.2 
per person) and duplications (1.3), with a smaller number of inversions (0.17).
It is of interest that ~40% of ultra-rare SV breakpoints in our dataset cannot be readily 
classified into the canonical forms of SV. This is a known limitation of short-read WGS, and 
such variants are often ignored. Formally, these SVs are of the generic “breakend” (BND) 
class33. We examined the 63,559 ultra-rare BNDs for insights into their composition and 
origin. Many (17.0%) appear to be deletions too small (<100 bp) to exhibit convincing read-
depth support, and that our pipeline conservatively classifies as BNDs (e.g., complex SV can 
masquerade as deletions). 2.4% of the ultra-rare BND stem from 1,542 “retrogene 
insertions” caused by retroelement machinery acting on mRNAs. This set of retrogene 
insertions is ~10-fold larger than prior maps34–36 and will be valuable for future studies. 
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5.5% of ultra-rare BNDs are complex genomic rearrangements with multiple breakpoints in 
close proximity (<100 kb). The remainder are difficult-to-classify variants involving either 
local (49.9% ≤1 Mb), distant intra-chromosomal (5.7% >1 Mb), or inter-chromosomal 
alterations (27.2%), many (78.0%) of which are classified as low-confidence SV calls. This 
final class is likely caused primarily by repetitive element variation, but is also expected to 
be enriched for false positives.
A variety of sporadic disorders are caused by extremely large and/or complex SV, but 
knowledge of the frequency and architecture of these dramatic alterations in the general 
population is incomplete due to the limitations of array-based methods used in prior large-
scale studies37, which fail to detect balanced events or resolve complex variant architectures. 
We observed 138 megabase-scale CNVs corresponding to a frequency of ~0.01 per 
individual; these include 47 deletions and 91 duplications, and affect a mean of 12.1 genes 
(Extended Data Fig. 8). Three individuals carried 2 megabase-scale CNVs, apparently due to 
independent mutations. We observed 19 reciprocal translocations (0.001 per individual), 
consistent with prior cytogenetic-based estimates38,39. Of these translocations, 14 affect one 
gene and 2 affect two genes, producing 1 predicted in-frame gene fusion (PI4KA:MGLL). 
We applied breakpoint clustering (as in 40) to identify ultra-rare complex rearrangements and 
discovered 33 complex SVs spanning >1 Mb (0.003 per individual). Most of these (20/33, 
60.6%) involve three breakpoints; however, we observed 5 large-scale rearrangements with 5 
or more breakpoints. Notably, when the entire SV size distribution is considered, 3.3% of 
ultra-rare SVs are complex variants, consistent with previous smaller-scale studies41–45.
Dosage sensitivity
A motivation for creating population-scale SV maps is to annotate genomic regions based on 
their tolerance to dosage changes and structural rearrangements, thus revealing the genes and 
non-coding elements most important (or dispensable) for human development and viability. 
The pLI score from ExAC/gnomAD28,29 has proven invaluable for this purpose but does not 
predict the effects of increased dosage or include non-coding elements.
We first generated DEL and DUP sensitivity scores for each gene based on the observed 
frequency of CNV in the combined dataset of 17,795 samples (as in 46, see Methods). The 
resulting scores correlate with the CNV scores from ExAC46, and with the DECIPHER 
haploinsufficiency score47 (Extended Data Fig. 9). Despite their relatively modest 
correlations with each other, all three measures are informative based on comparison to pLI, 
which was generated using an independent set of variants (SNV and indels). A combined 
score from multiple datasets performs better than any single score, and may be useful for 
interpreting rare SVs (Supplementary File 4).
We next performed a genome-wide analysis based on the frequency of dosage alterations in 
1 kb genomic windows (see Methods). Our current dataset is not large enough to predict 
dosage sensitive non-coding elements based on the absence of variation; however, we can 
investigate the relative sensitivity of genomic features in aggregate. As expected, we observe 
a strong depletion of CNV near coding exons that varies by proximity to the nearest exon as 
well as pLI of the corresponding gene (Fig. 4a). We therefore estimated odds ratios for 
depletion of CNV in each functionally annotated region, stratified by distance and pLI of the 
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nearest exon. The resulting dosage sensitivity scores mirror independent measures of 
selective constraint including LINSIGHT and PHASTCONS (Fig. 4b).
We also examined the relative dosage sensitivity of regulatory and epigenomic annotations 
from various projects48–53 (Fig. 4). Regulatory elements such as enhancers, polycomb 
repressors, DNase hypersensitivity sites, and transcription factor binding sites show strong 
sensitivity to dosage loss via deletion, whereas regions of inert non-coding annotations do 
not. The patterns of sensitivity to dosage gains via duplication are broadly similar, albeit 
weaker, with no obviously distinct patterns at (for example) enhancers, repressors or 
insulators. Dosage sensitivity of regulatory elements at “bivalent” genomic regions from 
ROADMAP is greater than their counterparts (e.g., enhancers vs. bivalent enhancers), 
suggesting that such elements may be under especially strong selection. Further, dosage 
sensitivity increases with the number of cell-types sharing a given annotation, suggesting a 
higher sensitivity for constitutive regulatory elements compared to those that act in a more 
cell-type specific manner.
DISCUSSION
Here, we have conducted the largest WGS-based study of SV in the human population to 
date. The sample size and use of deep (>20x) WGS allowed us to map rare SVs at high 
genomic resolution and estimate the relative burden of deleterious SV. Our data suggest that 
rare SV account for 4-11.2% of deleterious coding alleles and 17.2% of deleterious alleles 
genome-wide, an outsized contribution considering that SVs comprise merely ~0.1% of 
variants. Noteworthy is the burden of rare, strongly deleterious non-coding deletions 
apparent in our dataset: we estimate that a typical individual carries ~19 rare non-coding 
deletions that exhibit levels of purifying selection similar to LoF SNV and indels (of which 
there are ~34 per individual). These results indicate that comprehensive assessment of SV 
will improve power in rare variant association studies.
The public site-frequency maps reported here will also aid variant interpretation in smaller 
scale WGS-based studies (e.g., via allele frequency look-ups), in particular as they were 
generated via systematic joint analysis of large datasets from diverse populations (similar to 
ExAC/gnomAD28). One limitation is the high false negative rate for repetitive SV including 
mobile element insertions (MEI), short tandem repeats (STR) and multi-allelic CNVs 
(mCNV) due to the limitations of algorithms that rely on unique short-read alignments. 
Whereas we have reported a mean of 4,442 SV per genome, recent long-read analyses 
predict up to ~27,662 SV per genome, including STRs and other highly repetitive 
elements27. Although the inherent limitations of short-read WGS cannot be overcome, this 
resource could be made more comprehensive in future work with specialized algorithms 
tailored to MEI, STR and mCNV.
Finally, we have mined this resource to assess the dosage sensitivity of genes and non-
coding elements. At genes, our results complement existing estimates from exome 
sequencing and microarray data. At non-coding elements, we observe strong correlations 
with measures of nucleotide conservation, purifying selection, regulatory element activity, 
and cell-type specificity. Although our current sample size is insufficient to assess dosage-
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sensitivity of individual non-coding elements, this will become feasible as large-scale WGS 
resources from ongoing international programs become available.
METHODS
Generation of the “Build 38” (B38) callset
Per-sample processing.—This callset is derived from 23,559 individuals that were part 
of the CCDG program as well as 950 Latino samples from the PAGE consortium. All data 
was produced at one of the four CCDG-funded sequencing centers and aligned to genome 
build GRCh38 using each individual center’s functionally equivalent pipeline 
implementation25. Per-sample calling was performed on 23,547 samples using LUMPY23 
(v0.2.13), CNVnator54 (v0.3.3) and svtyper24 (v0.1.4). We excluded HLA, decoy or 
alternate contigs and regions of much higher than the expected copy number (>12 mean 
copies per genome across 409 samples) from SV calling with LUMPY (https://github.com/
hall-lab/speedseq/blob/master/annotations/
exclude.cnvnator_100bp.GRCh38.20170403.bed).
Per-sample QC.—We observed an excess of small (400 - 1000 bp) singleton deletions 
(i.e., present in only a single sample), suggesting a large number of false positives. On 
further investigation, this excess arose from differences between centers in library insert-size 
distribution. To reduce the number of false positive small deletions, deletions of ≤1000 bp 
were eliminated unless they had split read support in at least one sample. Subsequently, per-
sample quality control was performed to eliminate outlier samples. We removed 213 
samples where variant counts (for any SV type) were >6 median absolute deviations from 
the median count for that type.
Merging and cohort-level re-genotyping.—The remaining samples were processed 
into a single, joint callset using svtools22 (https://github.com/hall-lab/svtools) (v0.3.2), 
modified to allow for multi-stage merging. The code for this merging is available in a 
container via DockerHub (https://hub.docker.com/) (ernfrid/
svtools_merge_beta@sha256:126ad19ad1aae53d05127df93105d83d236ddfb11a8aa65344f0
d0aee936f919). Samples were merged using svtools lsort followed by svtools lmerge in 
batches of 1000 samples (or fewer) within each cohort. The resulting per-cohort batches 
were then merged again using svtools lsort and svtools lmerge to create a single set of 
variants for the entire set of 23,331 remaining samples. This site list was then used to 
genotype each candidate site in each sample across the entire cohort using svtyper (v0.1.4). 
Genotypes for all samples were annotated with copy number information from CNVnator. 
Subsequently, the per-sample VCFs were combined together using svtools vcfpaste. The 
resulting VCF was annotated with allele frequencies using svtools afreq, duplicate SVs 
pruned using svtools prune, variants reclassified using svtools classify (large sample mode), 
and any identical lines removed. For reclassification of chromosomes X and Y, we used a 
container hosted on DockerHub (ernfrid/svtools_classifier_fix:v1). All other steps to 
assemble the cohort above used the same container used for merging.
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Callset tuning.—Using the variant calling control trios, we chose a Mean Sample Quality 
(MSQ) cutoff for inversions (INV) and breakends (BNDs) that yielded approximately a 5% 
Mendelian error rate (ME). Inversions passed if: MSQ ≥ 150; neither split-read nor paired-
end lumpy evidence made up <10% of total evidence; each strand provided at least >10% of 
read support . BNDs passed if MSQ ≥ 250.
Genotype refinement.—Mobile element insertion (MEI) and deletion (DEL) genotypes 
were set to missing on a per-sample basis (https://github.com/hall-lab/svtools/blob/develop/
scripts/filter_del.py, commit 5c32862) if the site was poorly captured by split-reads. 
Genotypes were set to missing if the size of the DEL or MEI was smaller than the minimum 
size discriminated at 95% confidence by svtyper (https://github.com/hall-lab/svtools/blob/
develop/scripts/del_pe_resolution.py, commit 3fc7275). DEL and MEI genotypes for sites 
with allele frequency ≥0.01 were refined based on clustering of allele balance and copy 
number values within the datasets produced by each sequencing center (https://github.com/
hall-lab/svtools/blob/develop/scripts/geno_refine_12.py, commit 41fdd60). In addition, 
duplications were re-genotyped with more sensitive parameters to better reflect expected 
allele balance for simple tandem duplications (https://github.com/ernfrid/regenotype/blob/
master/resvtyper.py, commit 4fadcc4).
Filtering for size.—The remaining variants were filtered to meet the size definition of an 
SV (≥50 bp). The length of intra-chromosomal generic breakends (BNDs) was calculated 
using vawk (https://github.com/cc2qe/vawk) as the difference between the reported positions 
of each breakpoint.
Large callset sample QC.—Of the remaining samples, we evaluated per-sample counts 
of deletions, duplications, and generic breakends within the low allele frequency (0.1% - 
1%) class. Samples with variant counts exceeding 10 median absolute deviations from the 
mean for any of the 3 separate variant classes were removed. In addition, we removed 
samples with genotype missingness >2% . These QC filters removed a total of 120 
additional samples. Finally, we removed 64 samples that were identified as duplicates or 
twins in a larger set of data.
Breakpoint resolution
Breakpoint resolution was calculated using bcftools (v1.3.1) query to create a table of 
confidence intervals for each variant in the callset, but excluding secondary BNDs. Each 
breakpoint contains two 95% confidence intervals, one each around the start location and 
end location. Summary statistics were calculated in RStudio (v1.0.143; R version 3.3.3).
Self-reported ethnicity
Self-reported ethnicity was provided for each sample via the sequencing center and 
aggregated by the NHGRI Genome Sequencing Program (GSP) coordinating center. For 
each combination of reported ethnicity and ancestry, we assigned a super-population, 
continent (based on the cohort), and ethnicity. Samples where ancestry was unknown, but 
the sample was Hispanic, were assigned to the Americas (AMR) superpopulation. 
Summarized data are presented in Extended Data Table 1.
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As SNV calls were not yet available for all samples at the time of the analysis, relatedness 
was estimated using large (>1 kb), high-quality autosomal deletions and mobile element 
insertions with allele frequency >1%. These were converted to plink format using plink 
(v1.90b3.38) and then subjected to kinship calculation using KING55 (v2.0). The resulting 
output was parsed to build groups of samples connected through first degree relationships 
(kinship coefficient > 0.177). Correctness was verified by the successful recapitulation of the 
36 complete Coriell trios included as variant calling controls.
Callset summary metrics
Callset summary metrics were calculated by parsing the VCF files with bcftools (v1.3.1) 
query to create tables containing information for each variant/sample pairing or variant 
alone, depending on the metric. Breakdowns of the BND class of variation were performed 
using vawk to calculate orientation classes and sizes. These were summarized using Perl and 
then transformed and plotted using RStudio (v1.0.143; R version 3.3.3).
Ultra-rare variant analysis
We defined an ultra-rare variant as any variant unique to one individual or one family of first 
degree relatives. We expect the false positive rate of ultra-rare variants to be low because 
systematic false positives due to alignment issues are likely to be observed in multiple 
unrelated individuals. Therefore, we considered both high and low confidence variants in all 
ultra-rare analyses.
Constructing variant chains.—Complex variants were identified as in Chiang et al.3 by 
converting each ultra-rare SV to BED format and, within a given family, clustering 
breakpoints occurring within 100,000 bp of each other using bedtools56 (v2.23.0) cluster. 
Any clusters linked together by BND variants were merged together. The subsequent 
collection of variant clusters and linked variant clusters (hereafter referred to as chains) were 
used for both retrogene and complex variant analyses.
Manual review.—Manual review of variants was performed using IGV (v2.4.0). Variants 
were converted to BED12 using svtools (v0.3.2) for display within IGV. For each sample, 
we generated copy number profiles using CNVnator (v0.3.3) in 100 bp windows across all 
regions contained in the variant chains.
Retrogene insertions.—Retrogene insertions were identified by examining the ultra-rare 
variant chains constructed as described above. For each chain, we identified any constituent 
SV with a reciprocal overlap of 90% to an intron using bedtools (v2.23.0). For each variant 
chain, the chain was deemed a retrogene insertion if it contained one or more BND variants 
with +/− strand orientation that overlapped an intron. Additionally, we flagged any chains 
that contained non-BND SV calls, as their presence was indicative of a potential 
misclassification, and manually inspected them to determine if they represented a true 
retrogene insertion.
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Complex variants.—We retained any cluster(s) incorporating 3 or more SV breakpoint 
calls, but removed SVs identified as retrogene insertions either during manual review or 
algorithmically. In addition, we excluded one call deemed to be a large, simple variant after 
manual review.
Large variants.—Ultra-rare variants >1 Mb in length were selected and any overlap with 
identified complex variants identified and manually reviewed. Of 5 potential complex 
variants, one was judged to be a simple variant and included as a simple variant while the 
rest were clearly complex variants and excluded. Gene overlap was determined as an overlap 
≥1 bp with any exon occurring within protein-coding transcripts from Gencode v27 marked 
as a principal isoform according to APPRIS57.
Balanced Translocations.—Ultra-rare generic “breakend” (BND) variants, of any 
confidence class, connecting two chromosomes and with support (>10%) from both strand 
orientations were initially considered as candidate translocations. We further filtered these 
candidates to require exactly two reported strand orientations indicating reciprocal 
breakpoints (i.e. +−/−+, −+/+−, −−/++, ++/−−), no read support from any sample with a 
homozygous reference genotype, at least one split-read supporting the translocation from 
samples containing the variant, and <25% overlap of either breakpoint with any simple 
repeat (downloaded from ftp://hgdownload.cse.ucsc.edu/goldenPath/hg38/database/
simpleRepeat.txt.gz).
Comprehensive annotations from the Gencode v27 GTF (ftp://ftp.ebi.ac.uk/pub/databases/
gencode/Gencode_human/release_27/gencode.v27.annotation.gtf.gz) were used to 
determine the number of affected genes. A BED file of all introns was created by converting 
transcripts and exons to BED entries and subtracting all exons from their respective 
transcripts using bedtools (v2.23.0). To identify translocations affecting genes, the 
translocations were converted to BEDPE using svtools (v0.3.1), padded by 1 bp and 
intersected with introns using bedtools (v2.23.0). The number of unique chromosome/gene 
name pairs for each translocation was used to determine the number of affected genes 
affected by each breakpoint.
To determine if a translocation resulted in an in-frame fusion, we converted to BEDPE, 
padded by 1 bp and intersected the breakpoints with all introns using bedtools (v2.23.0). 
Each intron entry was then padded by 1 bp and intersected with the Gencode GTF file using 
bedtools (v2.23.0) and restricting to coding exons of the same transcript as the intron. Then, 
for each set of exons intersected by a given translocation, all combinations of transcripts 
were compared, taking into account their orientation and the orientation of the breakpoint, to 
determine if frame was maintained across the potentially fused exons. The resulting two 
candidate translocations were manually reviewed by reconstructing the transcript sequence 
of the fusion and translating the resulting DNA sequence using https://web.expasy.org/
translate/ to confirm a single open reading frame was maintained.
Generation of the “Build 37” (B37) callset
Per-sample processing.—This callset was constructed starting from a set of 8,455 
individuals: 8,181 samples from 8 cohorts sequenced at the McDonnell Genome Institute, as 
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well as 274 samples from the Simons Genome Diversity Project downloaded from EMBL-
EBI (https://www.ebi.ac.uk/ena/data/view/PRJEB9586). All samples passed standard 
production QC metrics and had a mean depth of coverage > 20X. Data were aligned to 
GRCh37 using the speedseq (v0.1.2) realignment pipeline. Per-sample SV calling was 
performed with speedseq sv (v0.1.2) using LUMPY (v0.2.11), cnvnator-multi, and svtyper 
(v0.1.4) on our local compute cluster. For LUMPY SV calling, we excluded high copy 
number outlier regions derived from >3,000 Finnish samples as described previously22 
(https://github.com/hall-lab/speedseq/blob/master/annotations/
exclude.cnvnator_100bp.112015.bed).
Per-sample QC.—Following a summary of per-sample counts, samples with counts of any 
variant class (DEL, DUP, INV, or BND) exceeding the median plus 10 times the median 
absolute deviation for that class were excluded from further analysis; 17 such samples were 
removed.
Merging.—The remaining samples were processed into a single, joint callset using svtools 
(v0.3.2) and the two-stage merging workflow (as described above): each of the 9 cohorts 
was sorted and merged separately in the first stage, and the merged calls from each cohort 
sorted and merged together in the second stage.
Cohort-level re-genotyping.—The resulting SV loci were then re-genotyped with 
svtyper (v0.1.4) and copy-number annotated using svtools (v0.3.2) in parallel, followed by 
combination of single-sample VCFs, frequency annotation, and pruning using the standard 
workflow for svtools (v0.3.2). A second round of re-genotyping with more sensitive 
parameters to better reflect expected allele balance for simple tandem duplications (https://
github.com/ernfrid/regenotype/blob/master/resvtyper.py, commit 4fadcc4) was then 
performed, followed by another round of frequency annotation, pruning, and finally 
reclassification using svtools (v0.3.2) and the standard workflow.
Callset tuning and site-level filtering.—Genotype calls for samples in 452 self-
reported trios were extracted, and Mendelian error rates calculated using a custom R script; 
we counted as a Mendelian error any child genotype inconsistent with inheritance of exactly 
one allele from the mother and exactly one allele from the father. Filtering was performed as 
described for the B38 callset: Inversions passed if: MSQ ≥ 150; neither split-read nor paired-
end lumpy evidence made up <10% of total evidence; each strand provided at least >10% of 
read support. Generic breakends passed if MSQ ≥ 250. SV of length <50 bp were removed, 
according to our working definition of ‘structural variation’.
Final sample-level filtering.—Nine samples with retracted consents, and two 
hydatidiform mole samples were removed from the callset. Subsequently, the numbers of qc-
passing, very rare (< 0.1% MAF) DEL, DUP, and BND per sample were determined. 
Excluding the samples in the Simons Genome Diversity cohort (which were expected, in 
general, to have unusually high counts of rare variants), we determined the median and 
median absolute deviation (MAD) of the per-sample counts of each type, and excluded 
outlier samples with a count exceeding the median+10*MAD of any type. Nine samples 
were removed in this way. Finally, kinship was estimated using KING (v2.0) based on high-
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quality, autosomal deletion and MEI calls with population allele frequency>1%. Each SV 
was annotated in the VCF according to the number of distinct, first-degree family clusters in 
which it was observed, as for the Build38 callset.
Principal components analysis.—A set of unrelated individuals (containing no first or 
second degree relatives) was extracted using KING (v2.0). PCA was performed using 
smartpca (version 13050) on a VCF of all high-quality DEL and MEI variant calls with 
population allele frequency > 1%. Eigenvectors were estimated based on the set of unrelated 
samples, and then all samples projected onto the eigenvectors.
Build38 (B38) SNV/indel callset generation and QC
Per-sample calling was performed at the Broad Institute as part of CCDG joint-calling of 
22,609 samples using GATK58 (https://www.biorxiv.org/content/early/2018/07/24/201178) 
HaplotypeCaller v3.5-0-g36282e4. All samples were joint called at the Broad using GATK 
v4.beta.6, filtered for sites with an excess heterozygosity value of more than 54.69, and 
recalibrated using VariantRecalibrator with the following features: QD, MQRankSum, 
ReadPosRankSum, FS, MQ, SOR, and DP. Individual cohorts were subset out of the whole-
CCDG callset using Hail v0.2 (https://github.com/hail-is/hail). Following SNV and indel 
variant recalibration, multiallelic variants were decomposed, and normalized with vt 
(v0.5)59. Duplicate variants and variants with symbolic alleles were then removed. 
Afterwards, variants were annotated with custom computed allele balance statistics, 1000 
Genomes allele frequencies29, gnomAD based population data28, VEP (v88)60, CADD30 
(v1.2), and LINSIGHT31. Variants having greater than 2% missingness were soft filtered. 
Samples with high rates of missingness (>2%) or with mismatches between reported and 
genetically-estimated sex (determined using plink v1.90b3.45 sex-check) were excluded. 
The LOFTEE plugin (v0.2.2-beta; https://github.com/konradjk/loftee) was used to classify 
putative LoF SNV and indels as high or low confidence.
Annotation of gene-altering SV calls
The VCF was converted to BEDPE format using svtools vcftobedpe The resulting BEDPE 
file was intersected (using bedtools (v2.23.0) intersect and pairtobed) with a BED file of 
coding exons from Gencode v27 with principal transcripts marked according to APPRIS57. 
The following classes of SV were considered putative gene-altering events: (1) DEL, DUP, 
or MEI intersecting any coding exon; (2) INV intersecting any coding exon and with either 
breakpoint located within the gene body; and (3) BND with either breakpoint occurring 
within a coding exon.
Gene-based estimation of dosage sensitivity
We followed the method of Ruderfer et al.46, to estimate genic dosage sensitivity scores 
using counts of exon-altering deletions and duplications in a combined callset comprising 
the 14,623 sample pan-CCDG callset plus 3,172 non-redundant samples from the B37 
callset. Build37 CNV calls were lifted over to build38 as BED intervals using crossmap 
(v0.2.1)61. We determined the counts of deletions and duplications intersecting coding exons 
of principal transcripts of any autosomal gene. In Ruderfer et al.46, the expected number of 
CNVs per gene was modeled as a function of several genomic features (GC content, mean 
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read depth, etc.), some of which were relevant to their exome read-depth CNV callset but not 
to our WGS-based breakpoint mapping lumpy/svtools callset. In order to select the relevant 
features for prediction, using the same set of gene-level annotations as in Ruderfer et al.46, 
we restricted to the set of genes in which fewer than 1% of samples carried an exon-altering 
CNV, and used l1-regularized logistic regression (from the R glmnet package62, v2.0-13), 
with the penalty chosen by 10-fold cross-validation. The selected parameters (gene length, 
number of targets, and segmental duplications) were then used as covariates in a logistic 
regression-based calculation of per-gene intolerance to DEL and DUP, similar to that 
described in Ruderfer et al.46. For deletions (or duplications, respectively), we restricted to 
the set of genes with <1% of samples carrying a DEL, to estimate the parameters of the 
logistic model. We then applied the fitted model to the full set of genes to calculate genic 
CNV intolerance scores as the residuals of the logistic regression of CNV frequency on the 
genomic features, standardized as z-scores and with winsorization of the lower 5th 
percentile.
Genome-wide estimation of deleterious variants
In order to estimate the relative numbers of deleterious SNV, indels, DELs and DUPs 
genome-wide in the normal population, we relied on a subset of 4,298 samples from the B38 
callset for which we had joint variant callsets for both SNVs/indels (GATK) and SVs 
(lumpy/svtools). Each SNV and indel was annotated with CADD30 and LINSIGHT31 scores 
as described above. CADD and LINSIGHT scores were converted to percentiles and 
singleton rates calculated for variants above each score threshold. CADD and LINSIGHT 
scores were then calibrated to a standard scale by matching singleton rates. Each DEL and 
DUP was annotated with CADD and LINSIGHT scores, calculated as the mean of the top 
10 single-base CADD or LINSIGHT scores, respectively, for the span of the CNV (similar 
to SVSCORE63). The CNV-level CADD and LINSIGHT scores were then standardized 
using the above calibration curves. Finally, each variant (SNV, indel, or CNV) was assigned 
a combined CADD-LINSIGHT score, calculated as the maximum of the 2 distinct scores.
The combined scores provided a means to rank, within each variant class, variants in order 
of deleteriousness. We calculated the singleton rate for the set of all LOFTEE high 
confidence protein-truncating SNV and indels in autosomal genes. We then estimated the 
number of deleterious variants of each type genome-wide by choosing the combined CADD-
LINSIGHT score threshold as the minimum value such that the singleton rate for the set of 
higher-scoring variants was greater than or equal to the singleton-rate for LOFTEE high-
confidence PTVs.
Annotation of non-coding elements
We divided the genome into 1 kb non-overlapping windows to investigate the rates of CNV 
occurrence relative to various classes of coding and non-coding elements, genome-wide. 
Windows intersecting assembly gaps or high-copy number outlier regions (as described 
above) and windows with fewer than 50% of bases uniquely mappable as determined using 
GEM-mappability (build 1.315)64 were excluded from analysis. Bed tracks of genomic 
annotations for the non-coding dosage sensitivity analysis were created as described below.
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The phastcons-20way65 conservation track was downloaded from the UCSC genome 
browser (rsync://hgdownload.cse.ucsc.edu/goldenPath/hg38/phastCons20way/
hg38.phastCons20way.wigFix.gz) and converted to bed format. The mean phastcons score 
for each 1 kb window was calculated using bedtools map. Quantiles of mean window-level 
phastcons scores were calculated and used as thresholds for the sensitivity analysis.
The LINSIGHT31 score track was downloaded from CSHL (http://compgen.cshl.edu/
~yihuang/tracks/LINSIGHT.bw). The 1kb genomic windows were lifted over to hg19 using 
crossmap (v0.2.1), annotated with mean per-window LINSIGHT scores using bedtools map 
and lifted back to GRChb38. Quantiles of mean window-level LINSIGHT scores were 
calculated and used as thresholds for the sensitivity analysis.
Genehancer52 enhancers were downloaded from GeneCards (https://
genecards.weizmann.ac.il/geneloc/index.shtml) and converted to bed format.
Vista51 enhancers were downloaded from LBL (https://enhancer.lbl.gov/cgi-bin/
imagedb3.pl?
page_size=20000;show=1;search.result=yes;page=1;form=search;search.form=no;action=se
arch;search.sequence=1), restricted to human enhancers, converted to bed format and lifted 
over to GRChb38 using crossmap.
Encode48 DNAse hypersensitivity sites and transcription factor binding sites were 
downloaded from UCSC (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/
wgEncodeRegDnaseClustered/wgEncodeRegDnaseClusteredV3.bed.gz, http://
hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeRegTfbsClustered/
wgEncodeRegTfbsClusteredV3.bed.gz) and lifted over to GRCHb38 using crossmap.
Oreganno66 literature-curated enhancers were downloaded from UCSC (http://
hgdownload.cse.ucsc.edu/goldenpath/hg19/database/oreganno.txt.gz) converted to bed 
format, and lifted over to GRChb38 using crossmap.
Sensitive50, transcription factor bound, ultra-conserved67, and HOT68 regions were 
downloaded from the funseq269 resources (http://archive.gersteinlab.org/funseq2.1.0_data).
Dragon enhancers were downloaded from DENdb70 (http://www.cbrc.kaust.edu.sa/
dendb/src/enhancers.csv.zip), converted to bed format, lifted over to GRChb37, and filtered 
for score>2.
Chromatin interaction domains derived from Hi-C on hESC and IMR90 cells71 were 
downloaded from http://compbio.med.harvard.edu/modencode/webpage/hic/, and distances 
between adjacent topological domains calculated with bedtools. When the physical distance 
between adjacent topological domains was <400 kb, these were classified as TAD 
boundaries; otherwise, they were classified as unorganized chromatin. The TAD boundaries 
and unorganized chromatin data were converted to bed format and lifted over to GRCh38 
using crossmap.
Roadmap chromatin state segmentations for 127 epigenomes were downloaded from 
Roadmap49 (https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/
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ChmmModels/coreMarks/jointModel/final/) and lifted over to GRCh38. Bedtools multiinter 
was used to determine the number of epigenomes in which each segment was present.
Dosage sensitivity of non-coding elements
To maximize power, DEL and DUP calls from the non-redundant combination of the B37 
and B38 callsets (as described above) were used for this analysis. Each window was further 
characterized by its distance to the nearest exon (the minimum distance between any point in 
the window and any point in the exon) and the pLI score of the gene corresponding to the 
nearest exon. The pLI score was set to zero for genes with pLI undefined. In the event that 
exons of 2 genes were equidistant to the window, the max of the two pLI scores was 
selected.
For a given SV type (DUP or DEL) and a given functional annotation (e.g., VISTA 
enhancers), each window was characterized by the presence or absence of one or more SV 
and the presence or absence of one of more genomic features. We observed a depletion of 
CNV in windows near exons, and in particular near exons of LoF-intolerant genes (see Fig. 
5a). As such, we used a Cochran-Mantel-Haenszel estimate of the odds ratios for each SV 
type/functional annotation, while stratifying for the proximity to the nearest exon as well as 
that exon’s LOF-intolerance (pLI). Because adjacent windows are not strictly independent 
observations – i.e., CNV or features may overlap adjacent windows inducing some spatial 
correlations – we used a block bootstrap method (resampling was performed on blocks of 10 
windows) to estimate robust confidence intervals.
Long-read validation
PacBio long-read sequences from nine 1000 Genomes Project (1KG) samples sequenced to 
deep coverage (>68-87x) at the McDonnell Genome Institute were used as an orthogonal 
means of validating SV calls. These PacBio data are available in SRA (see accessions in 
Supplementary Table 2) and were generated independently from the long-read data used by 
HGSVC to create the long-read SV callset used for sensitivity analyses described below27. 
The long-read sequences were aligned to GRCh38 using minimap272 (v2.16-r922; 
parameters -ax map-pb). Split-read alignments indicating putative SV were converted to 
BEDPE format56 as described previously23,24,73. Similarly, deletions or insertions longer 
than 50 bp contained within PacBio reads (as determined based on the cigar strings) were 
converted to BEDPE format. We used bedtools to judge the overlap between short-read SV 
calls and the long-read alignments. We judged an SV call to be validated when ≥2 long-
reads exhibited split-read mappings in support of the SV call. For a long-read mapping to 
support an SV call, we required that it must predict a consistent SV type (e.g., deletion) and 
exhibit substantial physical overlap with the SV call, where overlap can be met by either of 
the following criteria: (i) the two breakpoint intervals predicted by the SV call and the two 
breakpoint intervals predicted by the long-read split-read mapping overlap with each other 
on both sides, as determined by bedtools pairtopair using 100 bp of “slop” (-type -is both -
slop 100); or (ii) the SV call and the long-read split-read (or cigar-derived indel variant) 
exhibit 90% reciprocal overlap with one another (bedtools intersect -r -f 0.9). The above 
criteria for SV validation based on long-read support were selected based on extensive 
manual review of SV calls in the context of supporting data including read-depth profiles 
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and long-read mappings from all 9 samples, and are the basis for the validation rates 
reported in the main text and in Supplementary Table 3. However, we also show the range of 
validation rates that are obtained when using more lenient or strict measures of physical 
overlap, and when requiring a varying number of supporting PacBio reads (Extended Data 
Fig. 5), in both carriers and non-carriers of SVs from various classes. We also note that 3 of 
the 6 singleton SV calls that are not validated by long-reads appear to be true variants based 
on manual review of read-level evidence, where it appears that long-reads failed to validate 
true short-read SV calls due to subtle differences in how coordinates were reported at local 
repeats. Our FDR estimates may be conservative due to these effects.
To conduct a comparison to HGSVC using the three samples shared between our datasets 
(NA19240, HG00514, HG00733), all non-reference, autosomal SV calls for each of the 
three samples were extracted from the CCDG B38 and HGSVC27 Illumina short-read 
callsets. For HGSVC variants detected solely by read-depth analysis, for which genotype 
information was not available, a variant was defined to be non-reference if its predicted 
copy-number differed from the mode for that site across the 9 samples in that callset (which 
includes the parents of NA19240, HG00514, and HG00733). The short-read calls from our 
study and HGSVC for the three relevant samples were converted to BEDPE format using 
svtools vcftobedpe. The 3 single-sample VCFs from the HGSVC PacBio long-read SV 
callset were converted to BEDPE format in similar fashion. For HGSVC Illumina calls 
(which had been taken from a callset comprising 3 only trios, rather than a large cohort) 
variants were classified as rare if seen in only 1 of the 6 trio founders and either absent from 
or observed at frequency <1% in the 1KG Phase3 SV callset.
Long-read SV truth set construction
In order to evaluate the sensitivity of our callset, we constructed a high-confidence truth set 
from the comprehensive HGSVC long-read SV callset created using reference-guided de 
novo assembly27. The assembly-based long-read truth set includes all autosomal SV 
reported by HGSVC27 that were also validated by split-read alignments from the PacBio 
data generated independently at our center. Here, an HGSVC call was judged to be validated 
by long-read data when 2 or more long reads exhibited split-read mappings or cigar-derived 
SV calls that match the HGSVC call in terms of the predicted SV type and breakpoint 
intervals, allowing 100 bp of “slop” to account for positional uncertainty (bedtools pairtopair 
-type -is both -slop 100). To account for the variant classification scheme of the HGSVC 
callset – which only has two variant categories, INS and DEL – we allowed INS variants to 
be validated by long-reads suggesting either insertion or tandem duplication variants. 
Variants were classified as STRs if either >50% of sequence from both reported breakpoint 
intervals or >50% of sequence contained in the outer span of the variant overlapped a 
GRCh38 track of simple repeats downloaded from the UCSC Table Browser. The interval 
spanned by each variant was converted to bed format and lifted over to hg19 using 
crossmap. A combined CADD/LINSIGHT score was calculated for each variant based on 
the mean of the top 10 CADD-scoring and the mean of the top 10 LINSIGHT-scoring 
positions, as described in the section “Genome-wide estimation of deleterious variants” 
above.
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Liftover of the 1000 Genomes Phase3 SV Callset
The 1KG Phase3 SV callset was lifted over from GRCh37 to GRCh38 by first converting to 
BEDPE format using svtools vcftobedpe. The outer span of each variant was then converted 
to bed format and lifted over using crossmap61. For SVs that were not lifted over as 
contiguous intervals, discontiguous regions within 1 kb were merged using bedtools merge, 
and the largest of the merged variants were selected. The lifted-over bed interval was then 
converted back to BEDPE by padding each endpoint with 100 bp.
Assessment of sensitivity using the HGSVC long-read truth set
Sensitivity of the CCDG B38 and HGSVC Illumina short-read callsets to detect variants in 
the HGSVC long-read truth set was determined by converting each single-sample VCF to 
BEDPE format using svtools vcftobedpe and calculating overlaps using bedtools pairtopair, 
allowing for 100 bp of “slop”. For DEL calls, a variant was considered to be detected only if 
both breakpoints overlapped, and the type of the overlapping call was consistent with a 
deletion (i.e., DEL, MEI, CNV, or BND). For INS calls in the long-read callset, variants 
were considered detected if either breakpoint overlapped and the overlapping call was 
consistent with an insertion (i.e., DUP, INS, CNV, MEI, or BND).
Comparison with the 1KG Phase3 SV callset4 necessitated the use of a slightly different 
sensitivity metric, as 1KG analyzed the parents of HG00733 and NA19249, but not the trio 
offspring themselves. Since, with rare exception, germline variants present in the child 
should also be present in one of the two parents, the rate at which HGSVC long-read calls in 
the truth set were detected in at least one parent in each of the CCDG B38, HGSVC, and 
1KG callsets serves as an informative alternate measure of “sensitivity”.
Genotype comparison to 1KG
Genotype comparisons were performed for the 5 parental samples (NA19238, NA19239, 
HG00513, HG00731, and HG00732) present in both the CCDG B38 and the 1KG Phase3 
SV callsets. Each callset was subset (using bcftools) to the set of autosomal SVs with a non-
reference call in at least one of the 5 parental samples and converted to BEDPE format. 
Variants in the 1KG callset detected using read-depth methods only were excluded. Bedtools 
pairtopair (100 bp slop, overlap at both breakpoints) was used to determine the set of 
variants called in both the 5-sample CCDG callset and 5-sample 1KG callset, requiring 
consistent SV type. For each variant site in each sample, genotypes from the 2 callsets were 
compared. Results were tallied, and concordance rates and kappa statistics (‘irr’ package) 
were calculated in R.
CEPH pedigree analysis
Analyses of the three-generation CEPH pedigrees were performed on the set of 576 samples 
contained in the B37 callset that remained after excluding 21 samples that had been deemed 
low-quality and/or possibly contaminated based on analysis of a SNV/indel callset (A. 
Quinlan, Pers. Comm.). The remaining samples comprise 409 trios, which were used in the 
estimation of transmission rates. The counts of all high-quality SVs called heterozygous in 
one parent, homozygous reference in the other, and non-missing in the offspring were used 
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to estimate transmission rates by frequency class, with Wilson score confidence intervals 
calculated using R binconf.
Mendelian errors for all high-quality (filter=PASS) SV were calculated using plink 
(v1.90b3.45), with the output restricted to variant-trio observations in which all 3 genotypes 
(father, mother, and offspring) were non-missing. For each sample in the third generation 
(the “F2”; see Supplementary Fig. 6a) of any of the CEPH kindreds, Mendelian errors were 
counted by frequency class. The Mendelian error rate was calculated as the total number of 
Mendelian errors divided by the total number of non-reference, non-missing genotypes in F2 
generation samples for variants of that frequency class. “De novo” variants were defined as 
variants private to a single family where both parental genotypes are 0/0 and the offspring 
genotype either 0/1 or 1/1, and were obtained by parsing the plink output. (Note that these 
variant counts are used as callset quality metrics and do not necessarily represent true de 
novo mutations.)
Transmission rates for putative de novo variants were calculated by restricting to all high-
quality autosomal variants heterozygous in a second generation (“F1”) sample and 
homozygous reference in both of his/her parents (“P0” generation) and his/her F1 spouse. 
Each such variant was classified as transmitted if carried by any F2 offspring, with 
transmission rates calculated as the number of transmitted variants out of the total. “Missed 
heterozygous calls” were counted as the set of all family-private variants non-reference in at 
least two F2 offspring siblings, but homozygous reference in both of the F1 parents. The rate 
of missed heterozygous calls was calculated by dividing this count by the total count of 
family private variants carried by at least two F2 offspring siblings.
Extended Data
Extended Data Table 1.
(a) Ancestry, (b) ethnicity, and (c) continental origin of the samples analyzed in this study. 
For each table, the number of samples in the B37 and B38 callsets are shown separately, 
including the non-redundant combined set at right. Abbreviations are as follows: AFR, 
African; AMR, admixed American; EAS, east Asian; FE, Finnish European; NFE, non-
Finnish European; PI, Pacific Islander; SAS, South Asian.
a Ancestry Build 37 Build 38 Combined
AFR 3683 5501 6170
AMR 698 4165 4136
EAS 65 929 972
FE 2898 1207 2884
NFE 682 9588 10254
Not Specified 105 428 436
Other 123 751 777
PI 110 87 110
SAS 62 519 558
b Ethnicity Build 37 Build 38 Combined
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a Ancestry Build 37 Build 38 Combined
Hispanic 586 2829 2829
Non-Hispanic 3758 8022 10559
Not Specified 4082 12324 12959
c Continent Build 37 Build 38 Combined
African 66 24 66
Asian 32 1272 1272
Caribbean 279 1815 1815
East Asian 43 0 43
European 2985 1219 2971
North American 4641 18563 19800
Oceanic 41 18 41
Central Asian/Siberian 26 0 26
South American 274 264 274
South Asian 39 0 39
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Extended Data Figure 1. 
SV mapping pipeline. SV are detected within each sample using LUMPY. Breakpoint 
probability distributions are used to merge and refine the position of detected SV within a 
cohort, followed by parallelized re-genotyping, and copy number annotation. Samples are 
merged into a single cohort-level VCF file, variant types reclassified, and genotypes refined 
with svtools using the combined breakpoint genotype and read-depth information. Finally, 
sample-level QC and variant confidence scoring is conducted to produce the final callset.
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Extended Data Figure 2. 
The B37 callset. (a) Variant counts (y-axis) for each sample (x-axis) in the callset, ordered 
by cohort, where large (>1 kb) variants are shown in dark shades and smaller variants in 
light shades. (b) Variant counts per sample, where samples are ordered by self-reported 
ancestry according to the color scheme at right, using the abbreviations described in 
Supplementary Table 1. Note that African-ancestry samples show more variant calls, as 
expected. (c) Table showing the number of variant calls by variant and frequency class, and 
Mendelian error rate by variant type. (d) Histogram of allele count for each variant class, 
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showing alleles with counts ≤100. (e) Linkage disequilibrium of each variant class as 
represented by max R2 value to nearby SNVs, for N=1581 samples. Note that these 
distributions mirror those from our prior SV callset for GTEx3, which was characterized 
extensively in the context of eQTLs.
Extended Data Figure 3. 
. Note that African-ancestry samples show more variant calls, as expected. Note also that 
there is some residual variability in variant counts due to differences in data from each 
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sequencing center, but that this is mainly limited to small tandem duplications (see part a), 
primarily at STRs. (c) SV length distribution by variant class (d) Distribution of the number 
of singleton SVs detected in samples from different ancestry groups according to the 
abbreviations in Supplementary Table 1. Only groups with ≥1,000 samples in the B38 callset 
are shown, and each group was subsampled down to 1,000 individuals prior to allele 
frequency re-calculation. (e) Histogram showing the resolution of SV breakpoint calls, as 
defined by the length of the 95% confidence interval of the breakpoint-containing region 
defined by LUMPY, after cross-sample merging and refinement using svtools. Data are from 
N=360,614 breakpoints, 2 per variant. (f) Distribution of the number of SVs detected per 
sample in WGS data from each sequencing center (x-axis) for African and non-African 
samples, showing all variants (left), and those larger (middle) and smaller (right) than 1 kb 
in size. Per-center counts are as follows: Center A (1527 AFR, 2080 Non-AFR), Center B 
(408 AFR, 2745 Non-AFR), Center C (2953 AFR, 2226 Non-AFR), Center D (150 AFR, 
2534 Non-AFR). (g) Plots of Mendelian error (ME) rate (y-axis) by mean sample quality 
(MSQ) for each variant class, where dot size is determined by point density (see right) and 
the threshold used to determine high and low confidence SVs is shown by the vertical lines. 
All boxplots indicate the medians and first and third quartiles; whiskers extend 1.5 times the 
interquartile distance.
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Extended Data Figure 4. 
Principal components analysis for the B37 callset. PCA were calculated using an LD-pruned 
subset of high-confidence DEL and MEI variants, with MAF>1%. Ancestry is based on self-
report, using the color scheme at right, using the ancestry abbreviations described in 
Extended Data Table 1.
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Extended Data Figure 5. 
is based on the “100 bp slop or 90% reciprocal overlap” method, requiring ≥2 PacBio reads. 
(b) Validation rates by frequency class for variant carriers and non-carriers with increasing 
PacBio supporting read thresholds are shown using the same overlap method as in 
Supplementary Table 3. Variant counts per frequency class are as follows: singleton 
(N=133), rare (N=734), low frequency (N=1,361), and common (N=7,677).
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Extended Data Figure 6. 
Mendelian inheritance analysis in a set of 3-generation CEPH pedigrees comprising 409 
parent-offspring trios. (a) Example structure of a single CEPH pedigree indicating 
nomenclature of the parental (P0), first (F1) and second generation (F2). (b) Transmission 
rate of SVs from different allele frequency classes including SVs that are private to a single 
family (private), rare (<1%), low-frequency (“low”; 1-5%) and common (>5%). (c) Table 
showing the number and rate of Mendelian errors by allele frequency class. (d) Table 
Abel et al. Page 27













showing the number and rate of Mendelian errors for SVs private to a single family, for each 
SV type.
Extended Data Figure 7. 
Comparison of SV calls and genotypes to the 1000 Genomes (1KG) Phase3 callset4. (a) 
number of known and novel SVs in the B37 (left) and B38 (right) callsets, shown by 
frequency class. (b) Table showing the genotypes reported in our B38 (rows) callset versus 
1KG (columns) at SVs identified by both studies among the five samples included in both 
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callsets. (c) Table showing genotype concordance by SV type including the fraction of 
concordant calls and Cohen’s Kappa coefficient. (d) Distribution of correlation (R2) between 
genotype (GT) information determined by breakpoint-spanning reads and copy number 
(CN) estimates determined by read-depth analysis for the SVs shown in parts (b) and (c), 
when genotype information between the B38 and 1KG callset are concordant (left) or 
discordant (middle, right). At sites with discordant genotypes, correlation with copy number 
information is typically higher for genotypes from the B38 callset (middle) than the 1KG 
callset (right).
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Extended Data Figure 8. 
Ultra-rare SVs in the B38 callset (N=14,623). (a) Histogram showing the number of ultra-
rare SVs per individual, where ultra-rare is defined as “singleton” variants private to single 
individual or nuclear family. (b) Histogram showing the number of genes affected by ultra-
rare SVs larger than 1 Mb in size.
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Extended Data Figure 9. 
Correlations between dosage sensitivity scores for CNV in the combined callset (N=17,795). 
(a) Results for deletion variants. “ExAC score” is the published ExAC DEL intolerance 
score46. “CCDG score” is similarly calculated from our data, using CCDG deletions. “pLI” 
is the published loss-of-function intolerance score from ExAC28. “HI.Z” is the negative of 
the inverse-normal transformed haploinsufficiency score from DECIPHER47. 
“Ave.ccdg.exac” is the arithmetic mean of the CCDG and ExAC DEL intolerance scores. 
“Ave.ccdg.hi” is the arithmetic mean of the CCDG and HI-Z scores. Correlations shown are 
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Spearman rank correlations (rho), p-values are from the 2-sided spearman rank correlation 
test, N represents the number of genes included in the test. (b) Results for duplication 
variants, using the same naming conventions as in part (a).
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The public version of the B38 callset derived from 14,623 samples. (a) Self-reported 
ancestry. Abbreviations are as follows: AFR, African; AMR, admixed American; EAS, east 
Asian; FE, Finnish European; NFE, non-Finnish European; PI, Pacific Islander; SAS, South 
Asian. (b) Number of SVs per sample (x-axis, square-root scaled) by SV type (y-axis) and 
frequency class (panels labelled at top). SV classes are defined as: DEL, deletion; MEI, 
mobile element insertion; DUP, duplication; INV, inversion; BND, “break-end”, which is a 
generic term in the VCF specification for SV breakpoints that cannot be unequivocally 
classified. Minor allele frequency (MAF) bins are defined as: “ultra-rare” is private to an 
individual or family; “rare” is MAF<1%; “low-frequency” is 1%<MAF<5%; “common” is 
MAF>5%. (c) Number of high-confidence SVs by class and frequency bin. (d) CNV length 
distributions for each frequency class, defined as in part (b). (e) MAF distribution for SNV 
(N=85,687,916), indel (N=9,477,540), deletion (DEL, N=43,872) and duplication (DUP, 
N=10,805) variants for a subset of 4,298 samples for which GATK-based SNV/indel calls 
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were also available. All boxplots in this figure indicate the median and the first and third 
quartiles.
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Burden of rare gene-altering SV. (a) Per-sample mean number of gene alterations by type 
and frequency class, in 4,298 samples. (b) Per-sample mean number of rare (<1% MAF) 
high-confidence PTV by type and VEP consequence. (c) Per-sample mean number of rare 
(<1% MAF) SV-derived gene alterations by type. DEL and DUP are classified into ‘strong’ 
(affecting >20% of exons of principal transcript) and ‘weak’ (affecting <20% of exons of 
principal transcript) and subclassified as ‘internal’ (variant overlaps at least one coding exon, 
but neither the 3’ nor 5’ end of the principal transcript), 3prime (variants overlaps the 3’ end 
of the transcript), 5prime (variant overlap the 5’ end of the transcript), and complete (variant 
overlaps all coding exons in principal transcript), (d) (top) Fraction of rare (<1% MAF), 
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gene-altering variants occurring in low pLI (pLI<0.9) vs. high pLI (pLI>=0.9) genes, by 
type, size class, and gene region, in the B38 callset (N=14,623). Error bars indicate 95% 
confidence intervals (Wilson score interval). The dotted line indicates the expected fraction, 
assuming a uniform distribution of SV in coding exons. (bottom) Singleton rates for gene-
altering variants by type in the B38 callset (N=14,623), restricted to genes with pLI>0.1. 
Error bars indicate 95% Wilson score confidence intervals. See Supplementary Table 5 for 
the number of variants in each category.
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Estimation of genome-wide burden of high-impact functional alleles. (a) Singleton rates for 
SNV, by VEP consequence and percentile of combined VEP/CADD impact score. (b) 
Singleton rates for indels. (c) Singleton rates by variant type and percentile of combined 
VEP/CADD impact score. Here, “other LoF” indicates VEP-annotated protein-truncating 
variants (PTVs) that are not classified as high-confidence by LOFTEE. DELs and DUPs that 
intersect any coding exon of the principal transcript are classified as “coding”; otherwise 
they are “noncoding”. The horizontal line shows the singleton rate for all high confidence 
SNV/indel LoFs. (d) Per-sample mean number of “strongly deleterious” alleles genome-
wide, by type and frequency class. In panels (a)-(c), error bars indicate the 95% confidence 
interval (Wilson score method). See Supplementary Table 6 for counts of variants in each 
category.
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Dosage-sensitivity of functional annotations. (a) Fraction of 1 kb genomic windows 
containing at least one CNV, as a function of distance to the nearest coding exon and the pLI 
of that gene. (b) Depletion of CNV in conserved genomic regions. Log-odds ratios for the 
occurrence of CNV in highly conserved (based of LINSIGHT or PHASTCONS percentile) 
vs. less-conserved regions. Odds ratios are Cochran-Mantel-Haenszel estimates, stratified by 
distance to and pLI of nearest coding exon. (c) Log-odds ratios (estimated as in (b)) for the 
occurrence of CNV in 1 kb windows intersecting various functional annotation tracks. (d) 
Log-odds ratios (estimated as in (b)) for the occurrence of CNV in 1 kb windows 
overlapping roadmap segmentations, stratified by the number of roadmap tissues in which 
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the region is observed. All error bars indicate 95% confidence intervals estimated by block 
bootstrap.
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